Thanks doc, this reminds me of Generex amending the Clinical Study Agreement with The Henry M. Jackson Foundation for the Advancement of Military Medicine in 2011 to include more low her2 expressing subjects. I believe it was Dr. Craig Eagle, brought to advise AE by Joe when he was a consultant, that gave this guidance. That decision and amendment proved pivotal in targeting the proper BC groups that the vaccine could save. This report proves their move wise. Jmho.